Literature DB >> 15105530

Conserved amino acids 193-324 of non-structural protein 3 are a dominant source of peptide determinants for CD4+ and CD8+ T cells in a healthy Japanese encephalitis virus-endemic cohort.

Priti Kumar1, Paramadevanapalli Sulochana2, Gejjehalli Nirmala2, Maganti Haridattatreya2, Vijaya Satchidanandam1.   

Abstract

Our earlier identification of the non-structural protein 3 (NS3) of Japanese encephalitis virus (JEV) as a dominant CD4+ as well as CD8+ T cell-eliciting antigen in a healthy JEV-endemic cohort with a wide HLA distribution implied the presence of several epitopes dispersed over the length of the protein. Use of various truncated versions of NS3 in lymphocyte stimulation and interferon (IFN)-gamma secretion assays revealed that amino acids (aa) 193-324 of NS3 were comparable with, if not superior to, the full-length protein in evoking Th1 responses. The potential of this 14.4 kDa stretch to stimulate IFN-gamma production from both subtypes of T cells in a manner qualitatively and quantitatively similar to the 68 kDa parent protein suggested the presence within it of both class I and II epitopes and demonstrated that the entire immunogenicity of NS3 was focused on aa 193-324. Interestingly, this segment contained five of the eight helicase motifs of NS3. Analysis of variability of the NS3 protein sequence across 16 JEV isolates revealed complete identity of aa 219-318, which is contained within the above segment, suggesting that NS3-specific epitopes tend to cluster in relatively conserved regions that harbour functionally critical domains of the protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105530     DOI: 10.1099/vir.0.19698-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

Review 1.  Transcriptomic immune profiles of human flavivirus-specific T-cell responses.

Authors:  Alba Grifoni; Yuan Tian; Alessandro Sette; Daniela Weiskopf
Journal:  Immunology       Date:  2020-01-07       Impact factor: 7.397

Review 2.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 3.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

Review 4.  Japanese Encephalitis Vaccines.

Authors:  Vijaya Satchidanandam
Journal:  Curr Treat Options Infect Dis       Date:  2020-11-12

Review 5.  Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Authors:  Vandana Saxena; Tapan N Dhole
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

6.  Characterization of nonstructural protein 3 of a neurovirulent Japanese encephalitis virus strain isolated from a pig.

Authors:  Xufang Deng; Zixue Shi; Shuqing Li; Xiaodu Wang; Yafeng Qiu; Donghua Shao; Jianchao Wei; Guangzhi Tong; Zhiyong Ma
Journal:  Virol J       Date:  2011-05-09       Impact factor: 4.099

7.  Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice.

Authors:  Enyue Fang; Xinyu Liu; Xiaohui Liu; Ming Li; Ling Wang; Miao Li; Zelun Zhang; Yuhua Li; Yongxin Yu
Journal:  MedComm (2020)       Date:  2022-04-06

8.  Human T cell responses to Japanese encephalitis virus in health and disease.

Authors:  Lance Turtle; Tanushka Bali; Gemma Buxton; Savita Chib; Sajesh Chan; Mohammed Soni; Mohammed Hussain; Heather Isenman; Prachi Fadnis; Manjunatha M Venkataswamy; Vishali Satishkumar; Penny Lewthwaite; Ayako Kurioka; Srinivasa Krishna; M Veera Shankar; Riyaz Ahmed; Ashia Begum; Vasanthapuram Ravi; Anita Desai; Sutee Yoksan; Stefan Fernandez; Christian B Willberg; Henrik N Kloverpris; Christopher Conlon; Paul Klenerman; Vijaya Satchidanandam; Tom Solomon
Journal:  J Exp Med       Date:  2016-05-30       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.